Antinociceptive properties of oxymorphazole in the mouse

European Journal of Pharmacology

Volumn 473, Issue 2-3, 2003, Pages 143-148

  Wu, Hsiang en ^a   Sun, Han Sen ^a   Darpolar, Moses ^a   Dunn III, William ^b   Tseng, Leon F ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antinociception; Mouse; Opioid; Oxymorphazole

Indexed keywords

17 METHYL 6,7 DEHYDRO 3,14 DIHYDROXY 4,5 EPOXY 6,7:3',4' PYRAZOLOMORPHINAN; ACETIC ACID; DELTA OPIATE RECEPTOR ANTAGONIST; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE; UNCLASSIFIED DRUG;

ABDOMINAL WALL MUSCULATURE; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; HYDROPHILICITY; INHIBITION KINETICS; INJECTION; MALE; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; STIMULATION; TAIL FLICK TEST; TASK PERFORMANCE;

EID: 0042206723     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01912-5     Document Type: Article

References (19)

1. Calcagnetti D.J., Holzman S.G. Delta opioid antagonist, naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or morphine. Pharmacol. Biochem. Behav. 38:1991;185-190.
2. Coggeshall R.E., Carlton S.M. Receptor localization in the mammalian dorsal horn and primary neurons. Brain Res. Rev. 24:1997;28-66.
3. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
4. Follenfant F.L., Hardy G.W., Lowe L.A., Schneider C., Smith T.W. Antinociceptive effects of the novel opioid peptide BW443C compared with classical opiates; peripheral versus central actions. Br. J. Pharmacol. 93:1988;85-92.
5. Gulya K., Krivan M., Nyolczas N., Sarnyai Z., Kovacs G.L. Central effects of the potent and highly selective μ opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice. Eur. J. Pharmacol. 150:1988;355-360.
6. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
7. Hylden J.L.K., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 167:1980;313-316.
8. Kolesnikow Y.A., Jain S., Wilson R., Pasternak G.W. Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. J. Pharmacol. Exp. Ther. 279:1996;502-506.
9. Koster R., Anderson M., DeBeer E.J. Acetic acid for analgesic screening. Fed. Proc. 18:1959;412.
10. Narita M., Ozaki S., Ioka M., Mizoguchi H., Nagase H., Tseng L.F., Suzuki T. Different motivational effects induced by the endogenous μ-opioid receptor ligands endomorphin-1 and -2 in the mouse. Neuroscience. 105:2001;213-218.
11. Portoghese P.S. An approach to the design of receptor-type-selective non-peptide antagonists of peptidergic receptors: δ opioid antagonists. J. Med. Chem. 34:1991;1757-1762.
12. Roger H., Birch P.J., Harrison S.M., Palmer E., Manchee G.R., Judd D.B., Naylor A., Scopes D.I., Hayes A.G. GR94839, a kappa-opioid agonist with limited access to the central nervous system, has antinociceptive activity. Br. J. Pharmacol. 106:1992;783-789.
13. Schiller P.W., Nuyen T.M., Chung N.N., Dionne G., Martel R. Peripheral antinociceptive effect of an extremely mu-selective polar dermorphin analog (DALDA). Prog. Clin. Biol. Res. 328:1990;53-56.
14. Spanagel R., Almeida O.F., Shippenberg T.S. Evidence that nor-binaltrophimine can function as an antagonist at multiple opioid receptor subtypes. Eur. J. Pharmacol. 264:1994;157-162.
15. Strahs D., Weinstein H. Comparative modeling and molecular dynamics studies of the delta, kappa and mu opioid receptors. Protein Eng. 10:1997;1019-1038.
16. Tseng L.F., Collins K.A. Involvement of epsilon and kappa opioid receptors in inhibition of the tail-flick response induced by bremazocine in the mouse. J. Pharmacol. Exp. Ther. 259:1991;330-336.
17. Tseng L.F., Narita M., Suganuma C., Mizoguchi M., Ohsawa M., Nagase H., Kampine J.P. Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J. Pharmacol. Exp. Ther. 292:2000;576-583.
18. Wu H.E., Hung K.C., Mizoguchi M., Nagase H., Tseng L.F. Roles of endogenous opioid peptides in modulation of nocifensive responses to formalin. J. Pharmacol. Exp. Ther. 300:2002;647-654.
19. Xu W., Huang L.-F., Bauer L., Bhargava H., Dunn W.J. III Synthesis and opiate receptor binding properties of 17-methyl-6,7-dehydro-3,14-dihydroxy-4,5 α-epoxy-6,7:3′,4′-pyrimidinomorphinans. Bioorg. Med. Chem. Lett. 9:1999;33075-33380.